{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.4","upperLimit":"44.0","value":"34.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"108"}],"units":"Participants"}],"description":"ORR was defined as the rate an overall best response of either complete response (CR) or partial response (PR) by ICR assessment according to RECIST1.1. CR was defined as the disappearance of all target lesions and reduction in short axis of any pathologic lymphnode to \\<10 mm. PR was defined as ≥ 30% decrease in the sum of diameters of target lesions, taking the baseline sum diameters. Per planned analysis, ORR by ICR was assessed for the TNBC Target Population only.","dispersionType":"95% Confidence Interval","groups":[{"description":"Overall 144 participants with TNBC were enrolled in the study and received at least one dose of SG. Of these 144 participants, 108 received at least 2 prior therapies for metastatic disease and were treated with SG at a starting dose of 10mg/kg. These 108 participants were included in the analysis of safety and were referred to as the TNBC Target Population.","id":"OG000","title":"TNBC Target Population"}],"paramType":"NUMBER","populationDescription":"Target mTNBC: Participants with mTNBC who received at least 2 prior therapies for metastatic disease and who received SG at a dose of 10 mg/kg.","reportingStatus":"POSTED","timeFrame":"Up to data cutoff date of 01 March 2019 (maximum duration: 74 months)","title":"Objective Response Rate (ORR) by Independent Central Review (ICR)","type":"PRIMARY","unitOfMeasure":"Percentage of participants"}